VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
1.84
+0.08 (+4.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.76
Open1.78
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range1.76 - 1.89
52 Week Range1.44 - 4.00
Volume120,474
Avg. Volume85,657
Market Cap55.257M
Beta0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.62
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
Trade prices are not sourced from all markets
  • ACCESSWIRE8 days ago

    Volitionrx Limited to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Volitionrx Limited (NYSE MKT: VNRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time. ...

  • Associated Press8 days ago

    VolitionRX: 2Q Earnings Snapshot

    The Singapore-based company said it had a loss of 15 cents per share. In the final minutes of trading on Monday, the company's shares hit $1.91. A year ago, they were trading at $2.92. _____ This story ...

  • PR Newswire8 days ago

    VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended June 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, August 14, at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have had numerous highlights this quarter, with strong progress being made on many fronts.

  • PR Newswire9 days ago

    Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

    ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer. At 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1). "This is a very exciting outcome for us as we continue the development of our assays beyond colorectal cancer.

  • PR Newswire13 days ago

    VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

    ISNES, Belgium, Aug. 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Q™ platform technology for the diagnosis of endometriosis through a simple blood test. Volition has now commenced running its discovery grade assays through the cohorts and expects to report preliminary data over the coming months. Dr. Jake Micallef, Volition's Chief Scientific Officer, commented "Endometriosis is a potentially debilitating inflammatory condition in which the endometrial tissue that normally lines the inside of the uterus, grows outside the uterus, typically damaging the ovaries, fallopian tubes or other tissues of the pelvic cavity.

  • PR Newswire14 days ago

    VolitionRx Announces $9 Million Private Placement

    ISNES, Belgium, Aug. 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a definitive agreement with an existing accredited investor related to a private placement offering (PIPE) of 5 million shares of Volition common stock at a price of $1.80 per share, as well as a warrant to purchase up to an additional 5 million shares of Volition common stock at an exercise price of $3.00 per share payable in cash, which will result in gross proceeds to Volition before the deduction of estimated offering expenses of $9 million (excluding the proceeds from any exercise of the warrant). The warrant will have a term of one year from the closing date and be exercisable for a period of 6 months, commencing on the 6-month anniversary of the closing date. The private placement is expected to close on or about August 10, 2018, subject to customary closing conditions.

  • PR Newswire15 days ago

    VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Tuesday, August 14, 2018 at 8:30 am Eastern time ISNES, Belgium , Aug. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference ...

  • VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
    PR Newswire21 days ago

    VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today

    ISNES, Belgium, Aug. 1, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its first product the "Total Nu.Q™ Assay" research use only (RUO) kit, is ready and available for purchase through Active Motif, its Global Sales and Distribution Partner (https://www.activemotif.com/catalog/1266/NuQ-total-assay). This kit, based on Volition's proprietary Nucleosomics® technology, is the first in a range of kits due to be released over the coming months. Founder and Chairman of Active Motif, Joseph M. Fernandez, commented "We are continuously looking for innovative products in the field of epigenetics and believe that Nucleosomics® is a breakthrough technology. These RUO kits will provide researchers throughout the world with a new way to explore epigenetic modifications in circulating cell-free nucleosomes across different diseases from clinical samples.

  • PR Newswirelast month

    Volition Extends Global Reach of its Clinical Trial Program

    ISNES, Belgium , July 10 , 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its already impressive clinical trial program with the ...

  • PR Newswire2 months ago

    Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region

    ISNES, Belgium, July 2, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding of approximately $700,000 from the Walloon Regional Government. Including this latest amount, Volition has received approximately $3.7 million in non-dilutive funding from a number of local agencies to date. Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, "We are grateful to the Walloon Region, and in particular to the Vice-President of the Walloon Government and Minister for Economy, Industry, Research, Innovation, Digital, Employment and Training, Mr. Pierre-Yves Jeholet for his continued support of the Company.

  • ACCESSWIRE3 months ago

    SeeThruEquity Issues Update on VolitionRX Ltd. (VNRX) with a Target Price of $7.00

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Volition RX Ltd. with a Target Price of $7.00. VolitionRX Ltd. (NYSE American: VNRX) is a life sciences company focused on developing simple, easy-to-use blood-based tests to accurately diagnose a broad range of cancers and other conditions. VNRX's novel Nu.Q® family of blood-based diagnostics tests are based on the company's proprietary Nucleosomics® technology platform, which identifies and measures nucleosomes in the bloodstream.

  • Zacks Small Cap Research3 months ago

    VNRX: Triage Data Expected in Coming Weeks, Frontline By Year-End

    VolitionRx (VNRX) reported Q1 financial results and provided a business update. Initial studies could start in Asia prior to current year-end and if all goes to plan, initial commercial introduction could happen sometime next year.

  • PR Newswire3 months ago

    VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018

    ISNES, Belgium , May 14, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced its participation in the Bank of America Merrill Lynch 2018 Health Care Conference ...

  • Associated Press3 months ago

    VolitionRX: 1Q Earnings Snapshot

    The Singapore-based company said it had a loss of 17 cents per share. In the final minutes of trading on Thursday, the company's shares hit $2.24. A year ago, they were trading at $3.58. _____ This story ...

  • PR Newswire3 months ago

    VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update

    ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2018. Volition management will host a conference call tomorrow, May 11, at 8:30 a.m. U.S. Eastern Time to discuss these results.

  • PR Newswire3 months ago

    VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits

    ISNES, Belgium, May 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a Global Sales and Distribution Agreement with Active Motif for a range of Research Use Only ("RUO") kits, that are based on its proprietary Nucleosomics® technology. Founder and Chairman of Active Motif, Joseph M. Fernandez commented "We are continuously looking for innovative products in the field of epigenetics and believe Nucleosomics® is a breakthrough technology. The RUO kits are based on the same Nu.Q™ immunoassay technology as Volition's cancer screening panels and may be used to investigate a variety of clinical questions beyond Volition's core focus in cancer biomarkers.

  • PR Newswire4 months ago

    VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time ISNES, Belgium , May 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it ...

  • VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check
    Simply Wall St.5 months ago

    VolitionRx Limited (NYSEMKT:VNRX): Time For A Financial Health Check

    VolitionRx Limited (AMEX:VNRX) is a small-cap stock with a market capitalization of US$71.75M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...

  • ACCESSWIRE5 months ago

    SeeThruEquity Issues Update on VolitionRx (VNRX)

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...

  • ACCESSWIRE5 months ago

    Wired News – OpGen Announces Collaborator in Verification Study for Acuitas® Tests

    Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN ). If you want access ...

  • PR Newswire5 months ago

    VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock

    ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:  VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share for gross proceeds of $8.4 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition.  All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.

  • PR Newswire5 months ago

    VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

    ISNES, Belgium , March 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective ...

  • PR Newswire5 months ago

    VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

    Oppenheimer & Co. Inc. is acting as the sole book-running manager for the proposed offering.  National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD), is acting as a co-manager in connection with the offering. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.

  • PR Newswire6 months ago

    VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board

    ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr. Lee-Jen Wei, a professor of Biostatistics at Harvard University. Prof. Wei's main area of research is developing statistical methods for the design and analysis of clinical trials. Prof. Wei has developed numerous novel statistical methods used widely and is the author of more than 140 peer-reviewed publications.

  • Zacks Small Cap Research6 months ago

    VNRX: Q4 Results / Operational and Business Update

    By Brian Marckx, CFA NYSE:VNRX VolitionRx (NYSE:VNRX) reported Q4 results and provided a business update.  Relative to the financials, results continue to come in well within our expectations with Q4 operating ...